left-arrow right-arrow pinterest facebook google_plus linkedin

Gastrointestinal Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.

Alliance A021502

Status: Recruiting | Phase III 

Official Title: Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer

Study Purpose: The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. Learn more

Alliance A021602

Status: Recruiting | Phase III

Official Title: Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors after progression on everolimus.

Study Purpose: The purpose of this study is to learn if treatment with a drug called cabozantinib to prevent tumor growth is better, the same, or worse than placebo (a pill that contains no active drug). Learn more.

Boston Biomedical CanStem111P

Status: Recruiting | Phase III

Official Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Adult Pancreatic Adenocarcinoma

Study Purpose: To determine if adding BBI-608 to standard treatment will help subjects with metastatic pancreatic cancer live longer than those who only receive standard treatment. Learn more.


Status: Recruiting | Phase II

Official Title: Testing the Addition of the Drug Nivolumab after Surgery for High Risk Anal Cancer

Study Purpose: To find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy and radiation will prevent the anal cancer from returning. Learn more. 

HCRN GI14-198

Status: Recruiting | Phase II

Official Title: Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients.

Study Purpose: To find out the effects, good and/or bad, of adding the study agent ramucirumab to the usual chemotherapy regimen. Learn more


Status: Recruiting | Phase III

Official Title: Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose: To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer. Learn more

SWOG S1613

Status: Recruiting | Phase II

Official Title: Testing combination antibody treatment with Trastuzumab and Pertuzumab for advanced or metastatic colorectal cancer.  

Study Purpose: The purpose of this study is to compare any good or bad effects of using a combination of antibodies, Trastuzumab and Pertuzumab, to treating with the usual chemotherapy, Cetuximab and Irinotecan. Learn more